A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients
|Author:||Roininen, Saara1,2; Laine, Outi3,4; Kauppila, Marjut5;|
1Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital, Helsinki, Finland
2University of Helsinki, Helsinki, Finland
3Department of Internal Medicine, Tampere University Hospital, Tampere, Finland
4University of Tampere, Tampere, Finland
5Department of Internal Medicine, Turku University Hospital, Turku, Finland
6Department of Internal Medicine, Kuopio University Hospital, Kuopio, Finland
7Department of Internal Medicine, Oulu University Hospital, Oulu, Finland
|Online Access:||PDF Full Text (PDF, 0.3 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe201708158119
John Wiley & Sons,
|Publish Date:|| 2017-08-16
Cerebral venous thrombosis (CVT) covers up to a third of all venous thromboses (VTs) detected in patients with acute lymphoblastic leukemia (ALL). It usually hampers patients’ lives and may also endanger efficient leukemia treatment. Although many factors have been suggested to account for an elevated risk of VTs in patients with ALL, there still is a lack of studies focusing on CVTs and especially in the setting of adult ALL patients. We studied in our retrospective population-based cohort the occurrence, characteristics, as well as risk factors for VTs in 186 consecutively diagnosed Finnish adult ALL patients treated with a national pediatric-inspired treatment protocol ALL2000. In the risk factor analyses for VTs we found a distinction of the characteristics of the patients acquiring CVT from those with other kinds of VTs or without thrombosis. In contrast to previous studies we were also able to compare the effects of asparaginase in relation to CVT occurrence. Notably, more than half of the CVTs were diagnosed prior the administration of asparaginase which accentuates the role of other risk factors on the pathophysiology of CVT compared to truncal or central venous line (CVL) VTs in adult ALL patients.
|Pages:||1275 - 1285|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
Research grants from Weikko Wilhelm Peltonen Foundation (2014), and the Finnish Haematological Research Foundation (2016) and the Signe and Ane Gyllenberg Foundation (2016), and travel grants from the European Haematology Association (2016) and the University of Helsinki Fund (2016).
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.